Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judith E Epstein

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Malaria Journal|July 25, 2016
Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicityBradley W Hickey, Joanne M Lumsden, Sharina Reyes, et al.
Human Vaccines & Immunotherapeutics|August 1, 2013
Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infectionCindy Tamminga, Martha Sedegah, Santina Maiolatesi, et al.
Plos One|June 20, 2020
IMRAS-A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagentsBradley Hickey, Nimfa Teneza-Mora, Joanne Lumsden, et al.
Frontiers in Immunology|November 17, 2022
Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacyNatasha Kc, L W Preston Church, Pouria Riyahi, et al.
Plos One|October 18, 2011
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adultsMartha Sedegah, Cindy Tamminga, Shannon McGrath, et al.
Plos One|October 18, 2011
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP componentCindy Tamminga, Martha Sedegah, David Regis, et al.
Plos One|September 8, 2021
A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adultsMarvin J Sklar, Santina Maiolatesi, Noelle Patterson, et al.
Human Vaccines & Immunotherapeutics|November 16, 2012
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNAThomas L Richie, Yupin Charoenvit, Ruobing Wang, et al.
Plos One|March 5, 2013
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunityIlin Chuang, Martha Sedegah, Susan Cicatelli, et al.
JCI Insight|January 19, 2017
Protection against <i>Plasmodium falciparum</i> malaria by PfSPZ VaccineJudith E Epstein, Kristopher M Paolino, Thomas L Richie, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Malaria Journal|July 25, 2016
Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicityBradley W Hickey, Joanne M Lumsden, Sharina Reyes, et al.
Human Vaccines & Immunotherapeutics|August 1, 2013
Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infectionCindy Tamminga, Martha Sedegah, Santina Maiolatesi, et al.
Plos One|June 20, 2020
IMRAS-A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagentsBradley Hickey, Nimfa Teneza-Mora, Joanne Lumsden, et al.
Frontiers in Immunology|November 17, 2022
Increased levels of anti-PfCSP antibodies in post-pubertal females versus males immunized with PfSPZ Vaccine does not translate into increased protective efficacyNatasha Kc, L W Preston Church, Pouria Riyahi, et al.
Plos One|October 18, 2011
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adultsMartha Sedegah, Cindy Tamminga, Shannon McGrath, et al.
Plos One|October 18, 2011
Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP componentCindy Tamminga, Martha Sedegah, David Regis, et al.
Plos One|September 8, 2021
A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adultsMarvin J Sklar, Santina Maiolatesi, Noelle Patterson, et al.
Human Vaccines & Immunotherapeutics|November 16, 2012
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNAThomas L Richie, Yupin Charoenvit, Ruobing Wang, et al.
Plos One|March 5, 2013
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunityIlin Chuang, Martha Sedegah, Susan Cicatelli, et al.
JCI Insight|January 19, 2017
Protection against <i>Plasmodium falciparum</i> malaria by PfSPZ VaccineJudith E Epstein, Kristopher M Paolino, Thomas L Richie, et al.
Pageof 5